<DOC>
	<DOCNO>NCT00661830</DOCNO>
	<brief_summary>This trial conduct evaluate efficacy , safety tolerability combination gemcitabine plus sorafenib comparison gemcitabine plus placebo first-line palliative therapy chemo-naive advanced metastatic CCC . There strong scientific rationale explore role sorafenib combination gemcitabine advance CCC . Sorafenib novel signal transduction inhibitor prevents tumor cell proliferation angiogenesis blockade Raf/MEK/ERK pathway level Raf kinase receptor tyrosine kinases VEGF-R2 , R3 PDGFR-β . Mutations signal pathway display far common genetic alteration CCC overexpression correlate poor prognosis . Furthermore , evidence consistent meaningful pharmacokinetic interaction sorafenib gemcitabine , suggest sorafenib safely combined gemcitabine . Clinical result combination sorafenib gemcitabine phase I study pancreatic cancer suggest therapeutic effect , safety efficacy result together knowledge molecular pathology CCC provide rationale randomize , placebo-controlled phase II trial consist gemcitabine plus sorafenib advanced CCC .</brief_summary>
	<brief_title>Gemcitabine Sorafenib Advanced Biliary Tract Cancer ( GEMSO )</brief_title>
	<detailed_description />
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Male female patient age 18 year old Signed date informed consent start specific protocol procedure Adenocarcinoma gallbladder intrahepatic bile duct histologically proven hepatic metastasis earlier resect histologically proven biliary tract cancer Not amenable curative surgical resection With least one unidimensionally measurable target lesion nonirradiated ( treated photodynamic therapy , PDT ) area ( large diameter ≥ 1 cm ( spiral CT scan MRI ) ≥ 2 cm ( conventional CT scan ) With pain biliary obstruction control Cytologically histologically confirm Note : case uncertain biliary tract origin ( e.g. , intrahepatic CCCs ) , inclusion possible extensive search primary tumor ( thoracic abdomino pelvic CT scan , colonoscopy , upper digestive endoscopy , serum PSA level men mammography woman , FDGPET possible ) negative histological examination consistent bile duct adenocarcinoma , IHC positive cytokeratin 7 19 negative cytokeratin 20 [ Shimonishi , 2000 ] . No histological evidence hepatocellular carcinoma ( HCC ) No prior palliative ( radio ) chemotherapy ( gemcitabine fluoropyrimidinebased chemotherapy ) Note : previous adjuvant chemotherapy allow ( complete since ≥ 6 month contain gemcitabine platinum salt ) ; previous irradiation ( external radiotherapy , brachytherapy , chemoembolization ) PDT allow , provide least one unidimensionally measurable target lesion untreated area Resolution side effect prior surgical procedure grade ≤ 1 ( except laboratory value specify ) At least 4 week major surgery ( first dose study drug ) ECOG Performance Status 02 Surgery ( except diagnostic biopsy ) , external radiotherapy , brachytherapy , PDT within 30 day prior start treatment . Other tumor type adenocarcinoma ( e.g . leiomyosarcoma , lymphoma ) second cancer except patient squamous basal cell carcinoma skin carcinoma situ cervix effectively treat . Patients curatively treat disease free least 5 year discuss sponsor inclusion History cardiac disease : congestive heart failure &gt; NYHA class 2 ; active CAD ( MI 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension Any follow within 12 month prior start study treatment , : coronary/peripheral artery bypass graft , cerebrovascular accident transient ischemic attack , pulmonary embolism Ongoing cardiac dysrhythmias grade ≥ 2 , atrial fibrillation grade , QTc interval &gt; 450 msec male &gt; 470 msec female Hypertension control medication ( &gt; 150/100 mmHg despite optimal medical therapy ) History HIV infection Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) Known Central Nervous System tumor include metastatic brain disease Patients seizure disorder require medication ( steroids antiepileptic ) History organ allograft Patients evidence history bleed diathesis Active disseminate intravascular coagulation , patient prone thromboembolism Patients undergoing renal dialysis Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>advanced</keyword>
	<keyword>metastatic</keyword>
	<keyword>biliary</keyword>
	<keyword>tract</keyword>
</DOC>